Aviara Pharmaceuticals, Inc receives grant to collaborate with the Texas Heart Institute

(Texas Heart Institute) Aviara Pharmaceuticals, Inc. to collaborate with the Texas Heart Institute (THI) to develop a small molecule drug that targets inflammatory cell trafficking to the gut as a safe alternative to current treatment strategies in inflammatory bowel disease (IBD) under a Phase I Small Business Technology Transfer (STTR) award by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health (NIH).
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news